# RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

> **NCT05403242** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Advanced Gastroesophageal Adenocarcinoma

## Interventions

- **DRUG:** RC48-ADC
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT05403242
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-20
- **Primary completion:** 2025-09
- **Final completion:** 2026-09
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05403242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05403242, "RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05403242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*